Severe hypercalcemia due to teriparatide

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Osteoporosis is a prevalent metabolic bone disease characterized by reduced bone strength and increased fracture risk.
• Teriparatide, a recombinant human parathyroid hormone (PTH 1-34) analog, is an anabolic therapy used for osteoporosis treatment.
• It stimulates bone formation and resorption, improving bone microarchitecture in patients at high risk for fracture.

Purpose of the Study:

• To evaluate the efficacy of teriparatide in treating osteoporosis.
• To highlight the potential risk of severe hypercalcemia associated with teriparatide therapy.
• To emphasize the need for vigilant patient monitoring during treatment.

Main Methods:

• Review of teriparatide's mechanism of action in bone metabolism.
• Analysis of clinical indications for teriparatide in osteoporosis management.
• Assessment of reported adverse effects, focusing on hypercalcemia.

Main Results:

• Teriparatide demonstrates effectiveness in stimulating bone formation and improving bone quality.
• The therapy is indicated for high-risk osteoporosis patients who have not responded to or cannot tolerate other treatments.
• Severe hypercalcemia is a potential, life-threatening side effect that necessitates careful monitoring.

Conclusions:

• Teriparatide is an effective anabolic agent for osteoporosis.
• Clinicians must be aware of and monitor for severe hypercalcemia during teriparatide treatment.
• The occurrence of sustained severe hypercalcemia, though rare, warrants emphasis due to its potential severity.